EMA Authorised: Lorviqua (Lorlatinib) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Lorviqua (lorlatinib) for use in non-small cell lung cancer. The decision confirms EU approval of the product for this indication set by the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorviqua (lorlatinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Pfizer Europe MA EEIG. Decision date: 07/04/2026